证券研究报告 Q1 业绩超预期，毛利率再创新高 零跑汽车 (9863 HK) 港股通 | 华泰研究 | | 季报点评 | | --- | --- | --- | | 2025 年 5 月 | 20 日│中国香港 | 乘用车 | 公司公布一季度业绩：25Q1 实现营收 100.2 亿元（yoy+187.1%、qoq -25.6%），归母净利-1.3 亿元（24Q1/24Q4 分别为-10.1/+0.8 亿）。Q1 业绩 超出我们预期（Q1 前瞻中预计 Q1 亏损 5-10 亿），主要系 Q1 销量高增推 动营收同比+187.1%，且 Q1 毛利率达 14.9%再创新高。25 年公司将迎全 球化新车周期，叠加渠道端提前布局和下沉，LEAP3.5 架构进一步集成降 本，以及战略合作也将逐渐贡献收入，我们预计公司 25-27 年营收将保持高 速增长且毛利率持续提升，25 年有望实现全年盈利。维持买入评级。 Q1 销量高增推动营收同比+187.1%，毛利率 14.9%创历史新高 1）营收角度：①25Q1 公司汽车交付 87552 辆，同比+162.1%，强力推动 营收同比高增。②产品结构优化：25Q1 价格更高的 C ...

证券代码：920099 证券简称：瑞华技术 公告编号：2025-033 常州瑞华化工工程技术股份有限公司 投资者关系活动记录表 二、 投资者关系活动情况 活动时间：2025 年 5 月 16 日 15:00-16:30 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 □路演活动 □其他 活动地点：全景网"投资者关系互动平台"（https://ir.p5w.net） 参会单位及人员：通过网络方式参加公司 2024 年年度报告业绩说明会的投 资者。 上市公司接待人员：公司董事长徐志刚先生；公司董事、财务总监陆芝茵女 士；公司副总经理、董事会秘书谈登来先生；公司保荐代表人王站先生。 三、 投资者关系活动主要内容 本次业绩说明会通过年报视频解读等形式对公司情况及 2024 年经营业绩 情况进行了介绍。同时，公司就投资者在本次说明会中提出的问题进行了回复， 主要问题及回复如下： 问题 1：催化剂项目是否已开 ...

Core Insights - The industrial sector is moving towards precision and automation, increasing the demand for cleanliness and automation in processes, which presents broad application prospects for the company's cleaning equipment and intelligent solutions [1] - The company aims to capture market opportunities by enhancing technological reserves, improving operational efficiency, and strengthening cost control to achieve high-quality development [1] Business Overview - The company operates primarily in two segments: industrial cleaning systems and surface treatment, and intelligent equipment manufacturing [1] - In 2024, the industrial cleaning systems and surface treatment segment generated revenue of 1.264 billion yuan, accounting for 92.78% of total revenue [1] - The intelligent equipment manufacturing segment, which includes rubber intelligent equipment, digital factories, and electrical automation, achieved revenue of 95.96 million yuan, representing 7.04% of total revenue [1] Market Position and Strategy - The company has 69 years of experience in providing complete solutions for industrial cleaning and surface treatment, with a strong focus on high cleanliness and precision requirements [2] - The majority of the company's revenue comes from overseas, with domestic revenue at 110 million yuan (less than 10% of total revenue) and overseas revenue at 1.252 billion yuan (91.89% of total revenue) in 2024 [2] - The company employs a global and localized operational strategy for its overseas subsidiaries, focusing on serving regional markets [2] Financial Performance - The company has faced challenges, with net profits showing losses for five consecutive years, and a net loss of 21.76 million yuan in 2024, which slightly widened year-on-year [2] - Total revenue for 2024 was 1.362 billion yuan, a year-on-year decline of 5.51% [2] - The company reported a significant improvement in cash flow from operating activities, with a net cash flow of 94.84 million yuan [2] Future Outlook - The company plans to continue focusing on its core business, driving product innovation and market expansion to enhance its industry influence and consolidate its market position [2] - Efforts are being made to reduce costs, optimize resource allocation, and improve operational quality to achieve better performance [3]

深圳市理邦精密仪器股份有限公司 投资者关系活动记录表 | 投资者关 | □特定对象调研 □分析师会议 | | --- | --- | | 系活动类 | □媒体采访 ■业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位 | | | 名称及人 | 线上参与公司 2024 年度网上业绩说明会的全体投资者 | | 员姓名 | | | 时间 | 2025 年 5 月 19 日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 上市公司 | 董事长、总裁：张浩 | | 接待人员 | 董事、副总裁、董事会秘书、财务负责人：祖幼冬 | | 姓名 | 独立董事：郑全录 | | | 1、请问公司领导，目前的业务增长情况如何？未来有哪些具体的市场扩展 | | 投资者关 | 计划？ | | 系活动主 | 公司目前经营状况正常，各项业务按计划有序推进，具体经营数据和业务信 | | 要内容介 | 息请参考公司定期披露的公告。 关于未来市场拓展，一方面，公司将继续深耕 | | 绍 | 国内市场和夯实国内基础，挖掘潜在 ...

5月16日，针对近期网络上关于"荣耀（HONOR）退出印度市场"的传言，荣耀印度品牌负责人CP Khandelwal在X发布声明进行了回应。他表示，"我们注 意到网上流传着一些关于荣耀退出印度的虚假消息。让我们澄清一下——荣耀印度已经进驻，并且正在蓬勃发展。"他同时表示，他们已经准备好推出四 款新智能手机。 近期，有消息称使用荣耀设备的印度用户，从官方渠道收到了荣耀宣布停止在印度的运营和支持的通知，同时其Telegram群组将从"探索荣耀印度粉丝俱 乐部"更名为"阿尔卡特印度社区"。 据公开信息显示，荣耀此前曾退出过印度市场。2022年7月，时任荣耀CEO赵明曾公开表示，中国手机厂商在印度的日子确实不好过，荣耀团队已从印度 市场撤出，"我们对印度市场的理解是非常清楚的"。 在官宣退出印度市场一年后，荣耀产品很快重返印度。2023年8月，realme印度前首席执行官马达夫·谢斯（Madhav Sheth）辞去了realme印度的工作，并与 荣耀在印度的分销商PSAV合资成立了印度HONOR Tech公司，计划在印度推出荣耀手机。 荣耀方式回应称，荣耀公司在印度一直通过分销商的方式开展业务，目前在印度没有子公司也 ...

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 21 yuan [2][8]. Core Views - The medical device sector faced temporary pressure, while the pharmaceutical equipment segment showed steady growth. The company reported a slight increase in total revenue for 2024, reaching 10.021 billion yuan, and a net profit of 692 million yuan, reflecting a year-on-year growth of 5.75% [2][4]. - The company plans to distribute a cash dividend of 0.25 yuan per share (before tax) to all shareholders [2]. Financial Performance Summary - For 2024, the company achieved total revenue of 10,021 million yuan, with a year-on-year growth of 0.1%. The net profit attributable to the parent company was 692 million yuan, up 5.8% year-on-year [4][8]. - In Q4 2024, the company reported a revenue of 2,597 million yuan, a decrease of 3.63%, and a net profit of 75 million yuan, down 0.97% [2][4]. - For Q1 2025, the revenue was 2,308 million yuan, down 8.74%, and the net profit was 160 million yuan, a decrease of 23.97% [2][4]. Segment Performance - The medical device segment generated revenue of 3,735 million yuan in 2024, down 10.37%. The pharmaceutical equipment segment saw revenue of 2,171 million yuan, an increase of 12.90%. The medical trade segment reported 3,125 million yuan, up 8.04%, while medical services revenue was 834 million yuan, down 9.51% [2][8]. - The company is actively expanding its overseas market presence, achieving a 16.51% increase in overseas revenue to 281 million yuan in 2024 [2][8]. Profitability and Margin Analysis - The overall gross margin for 2024 was 26.06%, slightly down by 1.31 percentage points. The net profit margin improved to 6.90%, an increase of 0.14 percentage points, due to a decrease in sales and management expense ratios [2][8]. - In Q1 2025, the gross margin decreased to 23.79%, and the net profit margin fell to 6.99%, reflecting changes in product structure and increased expense ratios [2][8]. Earnings Forecast and Valuation - The company is expected to achieve net profits of 800 million yuan, 930 million yuan, and 1,030 million yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 15.4%, 16.2%, and 10.7% [2][4]. - The estimated earnings per share (EPS) for the next three years are projected to be 1.32 yuan, 1.53 yuan, and 1.69 yuan, with corresponding price-to-earnings (PE) ratios of 12, 10, and 9 [4][8].

每经记者｜刘明涛 每经编辑｜肖芮冬 白酒方面，Wind白酒指数本周跌幅虽为1.17%，但一线龙头白酒公司表现较强。其中，贵州茅台和山西汾酒本周分别上涨1.44%和0.83%，泸州老窖和五粮液 本周跌幅则为0.06%和0.38%，调整幅度较小，且跑赢白酒指数。今世缘和迎驾贡酒本周表现较弱，本周跌幅分别为3.12%和3.21%。在市值增长方面，贵州 茅台本周市值增长288.3亿元，市值增长在所有酒企里一枝独秀。 本周，白酒行业继续维持低位震荡，Wind白酒指数先扬后抑，周跌幅为1.17%，板块内个股普跌，迎驾贡酒和今世缘跌幅靠前。拉长时间看，这两只个股二 季度累计跌幅均超过10%，走势低迷。 四只白酒股二季度以来跌幅已超10% 值得关注的是，二季度以来，白酒指数季度跌幅环比明显缩窄，多只个股进入筑底阶段。但今世缘、洋河股份以及迎驾贡酒同期表现似乎有些"掉队"，二季 度以来累计跌幅均超过10%。 如果说洋河股份与迎驾贡酒股价低迷与其业绩低于预期有关，近年来成长迅速、已跻身"百亿俱乐部"的今世缘股价突然出现"疲态"，则可能与其业绩增速大 幅放缓相关。 随着2024年年报、2025年一季报披露完毕，投资者近期的目光开始 ...

丨证券研究报告丨 联合研究丨公司点评丨奥特维（688516.SH） [Table_Title] 奥特维：2024 年营收高增，2025 年加快海外市 场拓展及新品研发 报告要点 [Table_Summary] 公司发布 2024 年年报及 2025 年一季度报告，公司 2024 年营收实现高增，但 2024Q4 开始行 业整体经营压力有所体现。公司新接订单同比下降，但公司积极拓展海外市场，24 年实现海外 收入 15.31 亿元，同比+53.43%。公司将加快海外市场拓展步伐，形成收入增量。同时，由于 产品验收结构变化，公司盈利能力表现承压，但控费能力依然较强。公司继续夯实平台化业务 发展，对公司市场长期竞争力和盈利修复保有信心。 分析师及联系人 [Table_Author] 赵智勇 邬博华 曹海花 倪蕤 刘晓舟 SAC：S0490517110001 SAC：S0490514040001 SAC：S0490522030001 SAC：S0490520030003 SAC：S0490524030001 SFC：BRP550 SFC：BQK482 请阅读最后评级说明和重要声明 %% %% %% %% [Table ...

Core Viewpoint - Hendi Pharmaceutical's subsidiary, Wuhan Baike Pharmaceutical Development Co., Ltd., successfully passed an FDA inspection, confirming compliance with quality standards and enhancing its competitiveness in the international market [1] Group 1: FDA Inspection - The FDA inspection took place from March 10 to March 14, 2025, focusing on raw materials such as fludarabine phosphate, milrinone, granisetron, and furosemide [1] - The inspection report from the FDA confirmed the completion of the inspection, indicating that Baike Pharmaceutical met the necessary requirements [1] Group 2: Market Implications - The successful inspection demonstrates the company's commitment to maintaining quality systems that align with FDA standards, which is crucial for expanding into international markets [1] - This achievement is expected to enhance the competitiveness of the company's raw material products in the global market [1]

Group 1 - General Motors confirmed the restructuring of its high-end import vehicle platform, Daolang, in response to significant economic changes, indicating a strategic optimization of its operations in China [1] - The decision to restructure comes as the import vehicle sales account for less than 0.1% of General Motors' total sales in China, suggesting a focus on enhancing operational efficiency despite the low sales impact [1] Group 2 - BYD established a new automotive sales company in Baotou, expanding its sales network in the growing electric vehicle market, which is expected to enhance its local market influence [2] - This move reflects BYD's broader strategy of nationwide expansion in response to increasing demand for electric vehicles [2] Group 3 - Hyundai Motor Company broke ground on its first manufacturing plant in the Middle East, located in Saudi Arabia, marking a significant milestone in its global expansion strategy [3] - The new plant, a joint venture with the Saudi Public Investment Fund, is set to produce 50,000 vehicles annually, including electric and internal combustion engine models, starting in Q4 2026 [3] Group 4 - Ford Motor Company announced a recall of approximately 274,000 SUVs due to potential brake failure risks, which could negatively impact the brand's reputation despite the low percentage of affected vehicles [4] - This incident highlights the automotive industry's focus on safety issues and may lead consumers to scrutinize product quality more closely [4] Group 5 - GAC Trumpchi experienced a leadership change with Feng Xingya stepping down as chairman, replaced by He Xianqing, which may influence the company's future strategic direction and management style [5] - The leadership transition could generate new expectations regarding product innovation and market competitiveness for GAC Trumpchi [5]